M&A Deal Summary

LeMaitre Vascular Acquires Applied Medical - Angioscope

On September 19, 2014, LeMaitre Vascular acquired life science company Applied Medical - Angioscope for 420M USD

Acquisition Highlights
  • This is LeMaitre Vascular’s 2nd transaction in the Life Science sector.
  • This is LeMaitre Vascular’s largest (disclosed) transaction.
  • This is LeMaitre Vascular’s 3rd transaction in the United States.

M&A Deal Summary

Date 2014-09-19
Target Applied Medical - Angioscope
Sector Life Science
Buyer(s) LeMaitre Vascular
Deal Type Divestiture
Deal Value 420M USD

Target

Applied Medical - Angioscope

United States
Applied Medical - Angioscope is a fiberoptic catheters that allow visualization of the interior of peripheral arteries and veins.

Search 193,724 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

LeMaitre Vascular

Burlington, Massachusetts, United States

website


Category Company
Founded 1983
Sector Medical Products
Employees454
Revenue 154M USD (2021)
DESCRIPTION

LeMaitre Vascular is a provider of devices for the treatment of peripheral vascular disease. LeMaitre Vascular was founded in 1983 and is based in Burlington, Massachusetts.


DEAL STATS #
Overall 4 of 8
Sector (Life Science) 2 of 4
Type (Divestiture) 3 of 5
Country (United States) 3 of 6
Year (2014) 1 of 1
Size (of disclosed) 1 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-08-28 InaVein

Lexington, Massachusetts, United States

InaVein LLC is a provider of "TRIVEX". TRIVEX is a system comprised of capital equipment and disposables that enables less invasive removal of varicose veins. In this procedure, an illuminator instrument is inserted through a small incision into the leg, enabling visualization of varicose veins.

Buy $3M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-03-18 ProCol Vascular Bioprosthesis

United States

ProCol Vascular Bioprosthesis is a natural biological graft derived from a bovine mesenteric vein that provides vascular access for end-stage renal disease ("ESRD") hemodialysis patients. It is intended for the creation of a bridge graft for vascular access subsequent to at least one previously failed prosthetic access graft.

Buy -